1-3 of 3
Y. Kilinc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Treatment with the Once-Daily Oral Iron Chelator Deferasirox (Exjadereg], ICL670) Is Effective and Generally Well Tolerated in Pediatric Patients.

A. Piga, M. Bejaoui, Y. Kilinc, S. Perrotta, E. Vichinsky, C. Arrowsmith-Bensasson, E. Glimm, D. Alberti
Journal: Blood
Blood (2006) 108 (11): 1781.
https://doi.org/10.1182/blood.V108.11.1781.1781
Published: 2006
Journal Articles

Deferasirox (Exjade®, ICL670) Demonstrates Iron Chelating Efficacy Related to Transfusional Iron Intake in Pediatric Patients.

C. Kattamis, Y. Kilinc, S. Fattoum, A. Ferster, D. Gallisai, A. Maggio, M. F. Dresse, T. Klingebiel, K. Bourantas, D. Canatan, H. Maseruka, I. Gathmann, J. Ford
Journal: Blood
Blood (2005) 106 (11): 2692.
https://doi.org/10.1182/blood.V106.11.2692.2692
Published: 2005
Journal Articles

Mild and severe beta-thalassemia among homozygotes from Turkey: identification of the types by hybridization of amplified DNA with synthetic probes

JC Diaz-Chico, KG Yang, TA Stoming, DG Efremov, A Kutlar, F Kutlar, M Aksoy, C Altay, A Gurgey, Y Kilinc
Journal: Blood
Blood (1988) 71 (1): 248–251.
https://doi.org/10.1182/blood.V71.1.248.248
Published: 1988